期刊文献+

基质金属蛋白酶9与肾细胞癌生物学特性之间的关系

Plasma Matrix Metalloproteinase 9(MMP-9) Level Correlate with Biological Character of Renal Cell Carcinoma
暂未订购
导出
摘要 目的探讨MMP-9与肾细胞癌生物学特性之间的关系。方法肾细胞癌患者30例,其中有淋巴结转移5例。另设健康对照10名。对患者术前采空腹血,采用ELISA方法对被研究者血浆MMP-9含量进行检测。结果肾癌患者MMP-9水平高于正常健康人,P<0.001。有淋巴结转移者MMP-9浓度远高于没有转移的患者,P<0.05。结论研究表明血浆MMP-9水平与肾细胞癌生物学特性密切相关,可作为术后判定肿瘤复发、转移的指标。 Objective Try to find the correlation between MMP-9 level and Renal cell carcinoma(RCC). Methods Fasting blood were acquired from 30 patients of renal cell carcinoma before surgery therapy. Levels of MMP - 9 were determined by a sandwich ELISA method using Quantikine Human MMP - 9 Immunoassay. The concentration of MMP -9 was calculated after the standard curve. The comparison between each group was made by SPSS. Results MMP - 9 concentration of RCC patients was higher than healthy control ( P 〈 0.01 ), The levels of MMP -9 is significant difference between metastasis group( including lymph node metastasis). Conclusion These studies demonstrate an inverse relationship between plasma MMP -9 level and pathological characters of renal cell carcinoma. Higher levels of MMP - 9may indicates higher pathological stage and more opportunity of metastasis. Further studies are necessary to establish its usefulness in the clinical management of these patients. Metastasis can be found and treated local or systemic in time.
作者 孟琳
出处 《济宁医学院学报》 2008年第3期188-190,共3页 Journal of Jining Medical University
关键词 基质金属蛋白酶-9 肾肿瘤 转移 matris metalloproteinase Renal meoplasm metastasis
  • 相关文献

参考文献15

  • 1Slaton JW, Inoue K, Perrotte P, et al. Expression levels of genes thatregulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol,2001,158(2) :735
  • 2Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer, 1997,80 (Suppl) : 1529
  • 3Furukawa A,Tsuji M, Nishitani M, et al. Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive tumors transplanted in mice with severe combined immunodeficiency. Urology, 1998,51 (5) :849
  • 4Matrisian LM, Metalloproteinases and their inhibitors in matrix remodeling. Trends C, enet, 1990,6 (4) : 121
  • 5Tryggvason K, Huhtala P, Tuuttila A, et al. Structure and expression of type IV eollagenase genes. Cell Differ Dev, 1990,32 ( 3 ) :307
  • 6Woessner JF Jr. Matrix Metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J, 1991,5 (8) :2145
  • 7Sato H, Seiki M. Regulatory mechanism of 92 kDa type Ⅳ collagenase gene expression which is associated with invasiveness of tumor ceils. Oncogene, 1993,8 (2) :395
  • 8Kallakury BV, Karikehalli S, Haholu A, et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res ,2001,7 ( 10 ) :3113
  • 9Will H, Atkinson S J, Butler GS, et al. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progulatinase A and initiates autoproteolytic activation. Regulation by TIMP -2 and TIMP -3. J Biol Chem,1996,271 (29) :17119
  • 10Anderson IC. Combination therapy including a gelatinase inhibitor and cytotoxic agent, reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res,1996,56(4) :715

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部